Ozempic, Blood Pressure & Heart Health: Evidence & Biomarker C...

Last reviewed: June 1, 2026

Last updated: June 1, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists have demonstrated cardiovascular benefits in major clinical trials, including modest reductions in systolic and diastolic blood pressure alongside weight loss. The SUSTAIN-6 trial showed semaglutide reduced cardiovascular events by 26% in patients with type 2 diabetes and established cardiovascular disease.

For individuals considering GLP-1 therapy for hypertension and weight management, understanding your metabolic profile and genetic predispositions can help support more targeted conversations with your healthcare provider. PlexusDx emphasizes precision assessment—combining clinical evaluation with biomarker insights—to help identify who may benefit most from this treatment approach.

GLP-1 Mechanism in Blood Pressure and Cardiovascular Function

GLP-1 receptor agonists work through multiple pathways that may influence blood pressure. Beyond insulin secretion, these medications enhance vasodilation, reduce inflammation, and promote sympathetic nervous system modulation—all mechanisms relevant to hypertension management.

Clinical evidence indicates modest but clinically meaningful blood pressure reductions: semaglutide trials reported average systolic BP reductions of 3–5 mmHg in non-diabetic patients. These reductions occur alongside weight loss, which itself improves blood pressure control through reduced sodium retention and improved vascular function.

Cardiovascular and Metabolic Biomarkers to Consider

Before starting GLP-1 therapy, several biomarkers can inform your clinical assessment. These include lipid profile, fasting glucose, HbA1c, high-sensitivity C-reactive protein (hsCRP), and blood pressure itself. Your provider may also evaluate kidney function and electrolyte balance to ensure safety.

Biomarker	Clinical Relevance to GLP-1 Therapy
Systolic/Diastolic BP	Baseline measurement guides expected reduction range; targets <130/80 mmHg per ACC/AHA guidelines
LDL Cholesterol & Triglycerides	GLP-1s reduce triglycerides 15–30%; lipid response varies by baseline and weight loss
HbA1c & Fasting Glucose	Indicates glucose control status; GLP-1 efficacy strongest in diabetic or prediabetic range
Kidney Function (eGFR/Creatinine)	Determines GLP-1 safety and dosing; caution if eGFR <15 mL/min or on dialysis
hsCRP (Inflammation Marker)	Elevated hsCRP suggests cardiovascular risk; GLP-1s may reduce inflammation modestly

Genetic Predispositions and Peptide Pathway Response

Genetic variants in GLP-1 and metabolic pathways—such as GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—may influence how individuals respond to GLP-1 therapy. PlexusDx Precision Peptide Genetic Test evaluates these predispositions in peptide signaling, weight regulation, and appetite control pathways.

Individuals with certain genetic variants may experience greater or more modest weight loss responses, affecting blood pressure outcomes indirectly. This genetic context does not predict exact medication response but may help your provider identify whether GLP-1 therapy aligns with your metabolic profile and support more informed baseline expectations.

Who May Benefit: Provider Assessment Framework

GLP-1 therapy for hypertension and weight management is most commonly considered in patients with BMI ≥27 with hypertension or comorbidities (diabetes, cardiovascular disease, chronic kidney disease), or BMI ≥30 regardless of comorbidity. Baseline blood pressure must be monitored, as some patients require adjustment of concurrent antihypertensive medications.

Your healthcare provider will evaluate contraindications—including personal/family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe kidney disease, and acute pancreatitis risk. Pregnancy status, diabetic retinopathy severity, and gastrointestinal disorders also inform eligibility. Regular BP monitoring during treatment initiation helps assess response and medication adjustments.

How PlexusDx Supports a More Personalized Approach

PlexusDx Precision Peptide Genetic Test may help provide context about your underlying predispositions in GLP-1 receptor signaling, glucose metabolism, and weight regulation pathways. Understanding these genetic factors alongside clinical biomarkers supports a more comprehensive baseline assessment before and during GLP-1 therapy consideration. This genetic insight should always be interpreted with your qualified healthcare provider.

The Precision Peptide Genetic Test evaluates variants including GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—all relevant to peptide hormone response and metabolic function. These predispositions in peptide genetic pathways may provide context about baseline weight regulation and appetite control mechanisms, but do not predict exact medication response or guarantee blood pressure reduction outcomes.

Combining genetic insights with your clinical biomarkers—blood pressure, lipid profile, kidney function, inflammation markers—can support a more targeted conversation with your provider about GLP-1 candidacy, expected response timeframe, and realistic targets for both weight loss and cardiovascular benefit.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.